Cadrenal Therapeutics Inc (CVKD) FinancialsCVKDCadrenal Therapeutics Inc

Evaluating the bottom line, Cadrenal Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -275.16%, provide a clear picture of how effectively CVKD converts its operational activities into shareholder value.

In the context of the broader market, CVKD competes directly with industry leaders such as MDCX and HLSQ. With a market capitalization of $3.71M, it holds a leading position in the sector. When comparing efficiency, CVKD's gross margin of N/A stands against MDCX's N/A and HLSQ's 29.22%. Such benchmarking helps identify whether Cadrenal Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Cadrenal's financial performance shows ongoing losses, with net income consistently negative, the latest being -2,496,540 USD in Q1 2026. The company's gross profit has been negative for multiple quarters, indicating challenges in generating revenue. The current ratio is healthy at 3.73, suggesting good short-term liquidity, but the overall profitability remains a concern.